Grant: DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
McMaster University
$120,000.00
Characterizing Immune-Fibrinolytic Networks in Eosinophilic Nasal Polyps and Their Change with Biologic Therapy
EF 2025-26
Résumé
Chronic sinus disease with nasal polyps is a common condition that restricts airflow, causes repeated infections, and greatly reduces quality of life. It is driven by an overactive immune response called type 2 inflammation, the same process that underlies asthma and eczema. Current treatments often provide only short-term relief, and many patients require repeated surgeries. A new therapy, dupilumab, has shown remarkable success in shrinking polyps and improving symptoms. However, we still do not fully understand how the therapy works or why some patients benefit more than others.
In this study, I will examine nasal polyps collected from patients before and after treatment with dupilumab to learn how inflammation is resolved and how tissue repair occurs. Using advanced techniques that can measure dozens of proteins and genes at once in the same sample, I will track how immune cells, structural cells, and blood clotting systems interact in the polyp. I am especially interested in how dupilumab not only reduces inflammation but also restores balance in clotting and healing pathways that are disrupted in this disease.
The results will provide new insight into how this treatment works, why it is effective for many patients, and which biological pathways are most important for recovery. This knowledge could help physicians predict who will respond best to treatment, guide the development of new medicines, and reduce the need for repeated surgery. Beyond sinus disease, the findings will also be relevant to asthma and eczema, which affect millions of Canadians. By advancing both scientific understanding and patient care, this research has the potential to improve health, reduce the burden of chronic airway disease, and support more effective use of healthcare resources.
Programme
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
559333
Name
Denha Saven S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
DT1 (Biomedical and/or Clinical Research) CGRS Doctoral
Projecttitle
Characterizing Immune-Fibrinolytic Networks in Eosinophilic Nasal Polyps and Their Change with Biologic Therapy
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$120,000
Cihrequipment2
$0
Programname2
DRA : Canada Graduate Research Scholarship - Doctoral Program (CGRS D)
Keyworddelim
Biologic Therapy Mechanisms In Chronic Airway Disease; Cd4¿ T Cell Subsets (Th2, Tregs, Th2a); Coagulation And Fibrinolytic Pathways In Inflammation; Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (Ecrsw; Il-4/Il-13 Pathway Blockade (Dupilumab); Immune-Stromal And Immune-Epithelial Interactions; Single-Cell Rna Sequencing (Scrna-Seq); Spatial Multiplexed Proteomics And Transcriptomics; Translational Immunopathology; Type 2 Inflammation
Abstract
Chronic sinus disease with nasal polyps is a common condition that restricts airflow, causes repeated infections, and greatly reduces quality of life. It is driven by an overactive immune response called type 2 inflammation, the same process that underlies asthma and eczema. Current treatments often provide only short-term relief, and many patients require repeated surgeries. A new therapy, dupilumab, has shown remarkable success in shrinking polyps and improving symptoms. However, we still do not fully understand how the therapy works or why some patients benefit more than others.
In this study, I will examine nasal polyps collected from patients before and after treatment with dupilumab to learn how inflammation is resolved and how tissue repair occurs. Using advanced techniques that can measure dozens of proteins and genes at once in the same sample, I will track how immune cells, structural cells, and blood clotting systems interact in the polyp. I am especially interested in how dupilumab not only reduces inflammation but also restores balance in clotting and healing pathways that are disrupted in this disease.
The results will provide new insight into how this treatment works, why it is effective for many patients, and which biological pathways are most important for recovery. This knowledge could help physicians predict who will respond best to treatment, guide the development of new medicines, and reduce the need for repeated surgery. Beyond sinus disease, the findings will also be relevant to asthma and eczema, which affect millions of Canadians. By advancing both scientific understanding and patient care, this research has the potential to improve health, reduce the burden of chronic airway disease, and support more effective use of healthcare resources.
Competitiondate
202511
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Denha, Saven S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $120,000~ $0~